The present disclosure relates to a device for parenteral therapeutic agent delivery, more specifically methods and devices for continuous subcutaneous insulin infusion (CSII) configured for long term use with an extended therapeutic agent release coating.
CSII may be performed using an insulin infusion set (IIS). One example of an IIS device 100 is shown in
IIS devices may vary in size, shape, appearance, materials, and other features. In one example, the material used to construct the infusion catheter 134 may vary (e.g., the Contact Detach™ Infusion Set available from Animas Corporation uses a steel infusion catheter, whereas the MiniMed® Quick-set® Infusion Set available from Medtronic uses a plastic infusion catheter). In another example, the arrangement of line set tubing 122 may vary (e.g., the Contact Detach™ Infusion Set available from Animas Corporation uses two sets of a line set tubing coupled together via an intermediate strain-relief base, whereas the MiniMed® Quick-set® Infusion Set available from Medtronic uses a single line set tubing).
The patient's body may exhibit an inflammatory and/or foreign body response at the site of the infusion catheter or needle 134. This response at the infusion site may vary from patient to patient depending on various factors, including the patient's susceptibility to wound formation, the patient's associated tissue remodeling and the patient's sensitivity to the particular insulin formulation, including to insulin analogs, for example, and to phenolic excipients (e.g., meta-cresol, phenol, methylparaben, ethylparaben, butylbaraben, other preservatives, and combinations thereof) in the insulin formulation, for example. M-cresol, in particular, has been shown to induce inflammatory pathways, negatively impact human immune cell types in vitro, degrade lipid bilayers and neuronal cell membranes, and induce aggregation of proteins and initiate protein unfolding which might contribute to infusion site events.
Known IIS devices for CSII are currently indicated for two-to three-day (2-3 d) use. After even a short wear time, the inflammatory and/or foreign body response may impair the efficacy of the patient's infusion site, thereby limiting insulin uptake, increasing the risk of hyperglycemia, and limiting viable infusion site longevity. The limited wear time for IIS devices represents a two-to seven-times discrepancy compared with the wear time for continuous glucose monitors (CGMs), thus introducing an obstacle to achieving a convenient, fully integrated CSII/CGM artificial pancreas system.
A polymer coating including therapeutic agent particles for use with an extended wear infusion catheter is disclosed. Such a coating mitigates inflammation at the catheter site and provides introduction of medication at the site for an extended time of at least fourteen days to provide for continuous insertion of the catheter into a patient.
According to an illustrative embodiment of the present disclosure, an infusion device is provided including a base, an adhesive configured to couple the base to a skin of a patient, and a catheter having a therapeutic coating. The coating includes a polymer matrix and a therapeutic agent. The coating defines a thickness of at least 40 μm (micrometers) and a therapeutic agent loading of at least 30 wt. % (weight percent).
According to another illustrative embodiment of the present disclosure, an extended release coating is provided including a polymer matrix having a therapeutic agent comprising at least 45 wt. % of the coating. The coating defines a thickness of at least 40 μm.
According to yet another illustrative embodiment of the present disclosure, a method for applying a therapeutic coating to a catheter is provided. The method includes compounding a mixture of a polymer and a therapeutic agent to form a polymer matrix and therapeutic agent mixture with a therapeutic agent loading of at least 30 wt. %. The method further includes shaping the mixture to form a coating for application to a catheter. The coating defines a thickness of at least 40 μm.
The above mentioned and other features of this present disclosure, and the manner of attaining them, will become more apparent and the invention itself will be better understood by reference to the following description of embodiments of the present disclosure taken in conjunction with the accompanying drawings, wherein:
Corresponding reference characters indicate corresponding parts throughout the several views. Although the exemplification set out herein illustrates embodiments of the present disclosure, in several forms, the embodiments disclosed below are not intended to be exhaustive or to be construed as limiting the scope of the invention to the precise forms disclosed.
For the purpose of promoting an understanding of the principles of the invention, reference will now be made to the embodiments illustrated in the drawings and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended. Any alterations and further modifications in the described embodiments, and any further applications of the principles of the invention as described herein are contemplated as would normally occur to one skilled in the art to which the invention relates. One embodiment of the invention is shown in great detail, although it will be apparent to those skilled in the relevant art that some features that are not relevant to the present invention may not be shown for the sake of clarity.
An exemplary IIS device 200 is shown in
The infusion catheter 234 may be constructed of steel, plastic (e.g., polytetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), poly(propylene), high-density polyethylene (HDPE), low-density polyethylene (LDPE), ethyl vinyl acetate (EVA), copolymers thereof, and combinations thereof), or another suitable material. The infusion catheter 234 may be sufficiently thick to withstand implantation while being sufficiently thin to promote patient comfort. In some embodiments, the infusion catheter 234 may have a thickness less than about 200 μm, less than about 150 μm, or less than about 100 μm, for example. In some embodiments, the infusion catheter 234 may have an outer diameter of less than about 1 mm. In some embodiments, the infusion catheter 234 may have an outer diameter of about 0.7 mm to 0.8 mm.
A therapeutic coating 290 may be located on and/or in the device 200. The therapeutic coating 290 may be configured to release and deliver one or more therapeutic agents to the patient in an extended manner, as described further below.
The application of the therapeutic coating 290 to device 200 may vary. In certain embodiments, the therapeutic coating 290 may be incorporated (e.g., embedded) directly into device 200. In other embodiments, the therapeutic coating 290 may be applied (e.g., coated) onto an underlying surface of the device 200. In other embodiments, the therapeutic coating 290 may be applied onto a filtration mechanism that is loaded into the device 200.
The location of the therapeutic coating 290 on the device 200 may also vary. In the illustrated embodiment of
It is also within the scope of the present disclosure for the therapeutic coating 290 to be located along the fluid pathway of the device 200. More specifically, the therapeutic coating 290 may be located inside the line set tubing 222, inside the base connector 224, inside the infusion base 230, and/or inside the infusion catheter 234 such that the therapeutic coating 290 may dissolve into the insulin formulation traveling through device 200 for simultaneous delivery to the patient.
In the embodiments described herein, the infusion site may last at least 3 days, 5 days, 7 days, 10 days, or more, such as about 7 to 14 days or up to 21 days, which may reduce insulin waste, improve glycemic control, reduce scarring, and enable a once-weekly or once-biweekly change-over time frame for a fully integrated artificial pancreas system. The device 200 may include various other features designed to achieve longevity in CSII infusion site viability. Further features and descriptions of features may be found in U.S. Patent Application Publication No. 2019/0054233 to DEMARIA, et al., published Feb. 21, 2019, and titled “INFUSION SET WITH COMPONENTS COMPRISING A POLYMERIC SORBENT TO REDUCE THE CONCENTRATION OF M-CRESOL IN INSULIN”, the disclosure of which is hereby expressly incorporated by reference in its entirety.
An exemplary therapeutic coating 290 is shown in more detail in
The therapeutic coating 290 may include one or more first therapeutic agents 250 in the form of anti-inflammatory agents, including nonsteroidal anti-inflammatory therapeutic agents (NSAIDs). Exemplary anti-inflammatory agents include meloxicam, bromfenac, ibuprofen, naproxen, aspirin, plumbagin, plumericin, celecoxib, diclofenac, etodolac, indomethacin, ketoprofen, ketorolac, nabumetone, oxaprozin, piroxicam, salsalate, sulindac, tolmetin, rapamycin, dexamethasone, betamethasone, heparin, sirolimus, and paxlitaxel, for example. A device site, and its corresponding device 200, may last longer when a NSAID is locally administered, resulting in further benefits for the patient, including use of fewer devices, fewer needle sticks, and avoidance of hyperglycemia that is associated with an inflammatory response. Controlled release of a NSAID from the outer surface 235 of the infusion catheter 234 locally at the insertion site may allow the device site and its corresponding device 200 to last for an extended time period longer than 3 days, 5 days, 7 days, 10 days, or more, such as about 7 to 14 days or up to 21 days.
The therapeutic coating 290 may also include other or secondary therapeutic agents 252 alone or in combination with the anti-inflammatory, first therapeutic agents 250. Exemplary secondary therapeutic agents 252 include inhibitors of tyrosine kinase (e.g., masitinib), inhibitors of the matri-cellular protein Thrombospondin 2 (TSP2), inhibitors of fibrosis-stimulating cytokines including Connective Tissue Growth Factor (CTGF), inhibitors of members of the integrin family of receptors, Vascular Endothelial Growth Factor (VEGF), local insulin receptor inhibitors, antimicrobial agents (e.g., silver) and diffusion enhancing agents (e.g., hyaluronidase), for example. In one particular example, the therapeutic coating 290 includes the secondary therapeutic agent VEGF in combination with the anti-inflammatory agent dexamethasone, but other combinations are also contemplated.
The therapeutic coating 290 may also include one or more polymers to form a matrix 252 for the therapeutic agent(s), which may improve film or coating properties, improve solubility or elution properties, and/or impart a time-release effect to elution of the therapeutic coating 290 into the patient's SC tissue. Exemplary polymers include ethyl vinyl acetate (EVA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PLGA), polyhydroxyethylmethacrylate (PHEMA), poly(methacrylic acid) (PMAA), alginate (poly) phosphoryl chlorines and (poly) ester amides, polycaprolactone (PCL), thermoplastic polyurethane (TPU), hydroxypropyl methylcellulose (HPMC), co-povidone, copolymers thereof, and other combinations thereof, for example. The polymer matrix 252 may be a non-degradable material that remains substantially intact as the therapeutic agent 250, 258 diffuses from the polymer matrix 252 as described further herein.
Illustratively, as shown in
In some embodiments, smaller particle sizes of the therapeutic agents 250, 258 may be desirable. A smaller particle size may provide for faster dissolution (dissolve faster in fluid) and form better interconnectivity of the API (active pharmaceutical ingredient) network within the polymer, allowing for improved drug release. In other embodiments, larger particle sizes of the therapeutic agents 250, 258 may be desirable. In an example of an EVA-based system, a large particle size may lead to more sustained release of the therapeutic agents 250, 258 from the polymer matrix 252 in certain embodiments. Larger particle sizes of the therapeutic agents 250, 258 result in larger pores 254, which may allow a greater amount of the therapeutic agents 250, 258 to diffuse from further beneath the surface 256 of the polymer matrix 252 in some embodiments, resulting in more sustained release of the therapeutic agents 250, 258. The average particle size of the therapeutic agents 250, 258 may be about 1 μm to about 100 μm, more specifically about 5 μm to about 60 μm. In one embodiment, the average particle size for meloxicam is around 7.4 μm. A higher surface area to volume ratio of the extended release coating 290 may also result in more sustained release, as elution of the therapeutic agents 250, 258 results in a greater number of pores 254 over the polymer surface 256 to provide easier diffusion of the therapeutic agents 250, 258 from further beneath the surface 256, while also providing a thinner polymer matrix 252 from which the therapeutic agents 250, 258 elute.
For such embodiments, the materials produced are categorized as crystalline solid dispersions, in which the therapeutic agent 250, 258 in the crystalline form is dispersed and physically embedded in the polymer matrix 252. Over an extended time period, the mechanism of the therapeutic agent release involves the dissolution of the therapeutic agent 250, 258 from the polymer matrix 252, leaving behind voids or pores 254 in the polymer matrix 252, while leaving the polymer matrix 252 intact. As further therapeutic agent particles are released from the polymer matrix 252, the pores 254 become interconnected, and the interconnected pores can form channels, which may enhance the release of the therapeutic agent 250, 258 from within the polymer matrix 252. Furthermore, in some embodiments such as at least EVA and PCL systems, the coating surface texture impacts the therapeutic agent release kinetics. For example, a rougher surface texture has more surface area and provides channels near the surface of the coating that allow for fluid uptake, resulting in more API dissolution and release. In another example, a smoother surface texture may provide for improved insertion of the cannula, aesthetics, and coating integrity. Accordingly, the surface texture of the coating may be adjusted in the design of the system to facilitate achieving a desired release rate.
In one exemplary embodiment, a target release profile of the present disclosure provides between approximately 0.75 mg of released meloxicam and 1.75 mg of released meloxicam over 14 days per 9 mm device. The formulation may include a polymer matrix with an EVA grade of 2803A, 2820A, 3325A, or 4030AC, for example. Where the polymer matrix 252 has an EVA grade of 2803A, the formulation may include a vinyl acetate percentage of about 28% with a melt index of 3 dg/min. Where the polymer matrix 252 has an EVA grade of 2820A, the formulation may include a vinyl acetate percentage of around 28% with a melt index of 25 dg/min. Where the polymer matrix 252 has an EVA grade of 3325A, the formulation may include a vinyl acetate percentage of around 33% with a melt index of around 43 dg/min. Where the polymer matrix 252 has an EVA grade of 4030AC, the formulation may include a vinyl acetate percentage of about 40% with a melt index of around 55 dg/min. Table 1 provides exemplary formulations including EVA that substantially achieve this target release profile.
The therapeutic coating 290 may be loaded with a desired amount of the therapeutic agents 250, 258, such as about 20-75 wt. %, more specifically about 30-75 wt. %, more specifically 30-65 wt. %, more specifically about 35-60 wt. %, more specifically about 40-55 wt. %, and more specifically about 45-55 wt. %. As shown in Table 1, above, for example, for EVA coatings, the therapeutic coating 290 may include a meloxicam loading of about 55-70 wt. %, which corresponds to about 42-58 vol. % meloxicam, respectively. To mitigate the risk of poor coating integrity so that the polymer matrix 252 remains substantially intact as the meloxicam is released, the preferred loading weight percentage of meloxicam may be about 55 wt. % or less, so that over 50 vol. % of the coating is comprised of EVA, for example. In other embodiments including a PCL-meloxicam coating, the therapeutic coating 290 may include a meloxicam loading of about 30-65 wt. %, more specifically about 50 wt. %.
The coating thickness of the therapeutic coating 290 may be from about 20 μm to about 200 μm, more specifically about 40 μm to about 160 μm. For example, the coating thickness may be about 20 μm, about 40 μm, about 60 μm, about 80 μm, about 100 μm, about 120 μm, about 140 μm, about 160 μm, about 180 μm, or about 200 μm. The coating thickness may vary based on the average particle size of the therapeutic agents 250, 258. In certain embodiments, the coating thickness may be about 3 to about 30 times larger than the average particle size of the therapeutic agents 250, 258, such that the therapeutic coating 290 can accommodate several “layers” of therapeutic agent particles 250, 258 beneath the surface 256.
In some embodiments, the thicknesses of the coatings 290 may depend on the polymer-meloxicam formulation and catheter geometry, including liner thickness and catheter length. For example, the range of an exemplary PCL-meloxicam coating thicknesses may be about 48-224 μm, including about 48-101 μm for a 13 mm catheter, about 67-139 μm for a 9 mm catheter, or about 96-224 μm for a 6 mm catheter. In embodiments limiting the overall diameter of the catheter to 1 mm or less, the maximum coating thicknesses, depending on the liner thickness as discussed further herein, may be about 160-210 μm for liner thicknesses of about 0.07-0.12 mm.
In certain embodiments, and as shown in
A solvent-based method may be used to produce the therapeutic coating 290 of
The solution containing the solvent, dissolved polymer, and therapeutic agent is then applied to the outer surface 235 of the infusion catheter 234 of
Finally, the solvent is permitted to evaporate from the solution, leaving behind the therapeutic coating 290 of the polymer matrix 252 and therapeutic agents 250, 258 on the infusion catheter 234.
A melt-based molding method may be used to produce the therapeutic coating 290 of
In some embodiments, single screw or twin screw hot melt extrusion may be utilized to form the therapeutic coating 290 of
In one embodiment, a two-stage process is utilized. The twin screw extrusion is used for compounding to produce pellets of homogenous polymer-therapeutic agent material. In a second extrusion stage, the pellets of polymer-therapeutic agent material are fed into a single-screw extrusion process as the shape forming step, such as over-extrusion for applying a polymer-therapeutic coating onto tubing. In other embodiments, the secondary stage could be micro-injection molding, in which the pellets of polymer-therapeutic agent are fed into a hopper and injection molded to form a catheter or catheter coating 234 via overmolding or two-shot molding.
For production of bi-layer drug eluting catheters, twin-screw extrusion may be used for compounding to mix a polymer and a therapeutic agent to produce homogenous polymer-therapeutic pellets at the target therapeutic agent loading level (wt. %). A single screw extrusion process may be used as a shape forming step. The options for the single screw extrusion may include (1) over-extrusion, where the polymer-therapeutic is applied as a coating onto tubing (polymer liner and tubing produced separately); and (2) co-extrusion of bi-layer tubing where the inner layer (liner) is a polymer without a therapeutic agent (e.g., HDPE, Tritan, PTFE, TPU, FEP, etc.) and the outer layer, or coating, is a polymer-therapeutic coating. The coated tubing is an intermediate product and requires post-processing for forming the catheter. The post-processing includes: (1) cutting the coated tubing to the target length for a 6 mm, 9 mm, or 13 mm catheter; (2) completing a flaring process at the proximal end and press fitting the bushing to the proximal end; and (3) completing a catheter tipping process to form the taper of the outer diameter and the inner diameter of the catheter at the distal end. The bi-layer catheter would then be assembled as part of an infusion set.
Injection Molding Method for Tubes and other Shapes
In some embodiments, an injection molding method may be utilized to form molded shapes of polymer-API material. Two exemplary designs of tubes are illustrated in
A micro-injection molding method may involve a two-shot mold or over-mold. The mold may be designed to produce a catheter that includes the bushing at the proximal end and the taper at the distal end, and therefore, not require post-processing steps. The first shot may be a polymer without a therapeutic agent as the material for the liner and the bushing (e.g., HDPE, etc.), and the second shot may be a polymer loaded with the therapeutic agent. Specifically, the polymer-meloxicam pellets produced from a twin-screw extrusion compounding step may be fed into the hopper of a micro-injection molding machine for the second shot. The final product from the two-shot micro-injection molding process may be a bi-layer drug-eluting catheter, which may be assembled as part of an infusion set. An exemplary catheter 400 produced by micro-injection molding is illustrated in
The following examples describe the manner, process of making, and/or process of using the present disclosure and are intended to be illustrative rather than limiting.
Quantities of EVA and meloxicam were dissolved in a chloroform solvent. Using a pipette, the EVA-meloxicam solution was dispersed onto a Teflon surface, and the chloroform was then allowed to evaporate, forming a film or coupon. Once the chloroform was evaporated, the film was peeled from the surface of the Teflon while remaining substantially intact. The films were each immersed in phosphate-buffered saline (PBS) to yield a target therapeutic agent concentration, assuming 100% therapeutic agent release rate. The volume of PBS used varied depending on the measured film weight. The coupons included a therapeutic agent loading of 40 wt. %, 55 wt. %, or 70 wt. %. Each coupon was subcutaneously implanted in a rat. The coupons may or may not be siliconized immediately prior to implantation. For a two-week testing period, whole blood was drawn from the rats, plasma was separated from the whole blood, and plasma meloxicam levels were measured by HPLC-MS.
The dosing of meloxicam in each of the four formulations may differ according to the meloxicam loading level and thickness of the coating.
As shown in
As mentioned above, the film may be coated with silicone before being implanted.
Graph 524 illustrates the effects of silicone oil on the normalized-to-dose release profile of films having an EVA grade of 3325A with a meloxicam loading of 55 wt. %, wherein the solid line 524a illustrates the average release profile of films without siliconization, the dashed line 524b illustrates the average release profile of films siliconized with high viscosity oil, and the dotted line 520c illustrates the average release profile of films siliconized with low viscosity oil. Graph 526 illustrates the effects of silicone oil on the normalized-to-dose release profile of films having an EVA grade of 4030AC with a meloxicam loading of 70 wt. %, wherein the solid line 526a illustrates the average release profile of films without siliconization, the dashed line 526b illustrates the average release profile of films siliconized with high viscosity oil, and the dotted line 526c illustrates the average release profile of films siliconized with low viscosity oil.
The silicone layers (especially the high-viscosity silicone layers of lines 520b, 522b, 524b, and 526b) serve as a diffusion barrier, which results in reduced and/or delayed meloxicam uptake as shown, especially at the initial burst elution as shown in
The in vivo release profiles were calculated using a deconvolution model for translating the rat plasma profile concentrations to in vivo release profiles. The deconvolution method is a technique to estimate an input function, which are the release profiles from EVA-meloxicam coupons, given the corresponding input-response function, which are the plasma concentration data from EVA-meloxicam coupons, and the impulse response function, which is the plasma concentration profile following an IV bolus dose, for the system. The key assumptions for this model are as follows: (i) subcutaneous dose showed very fast adsorption and is assumed to behave like an IV dose, and therefore has been used as the impulse response function, (ii) linearity: f(D1+D2)=f(D1)+f(D2), and (iii) time invariance: f(D) has the same shape no matter when D is given. The in vivo release profiles illustrated in
Referring to the example of
Now referring to
In this example, sheets of meloxicam and ethyl vinyl acetate (EVA) were formed by melt compounding and compression molding with nominal thicknesses of 90 μm, 120 μm, or 150 μm. Mini tensile bars were die cut from these sheets using a clicker press, then the actual thickness of each mini tensile bar was measured using a micrometer.
The mini tensile bars were pulled in triplicate in an Instron with a 5 in/min extension rate at 23° C. and 50% RH to measure the stress at maximum load, the strain at maximum load, and the Young's Modulus of each mini tensile bar.
The stress measurements are set forth in
The following effects are observed from the example of
The strain measurements are set forth in
The following effects are observed from
The Young's Modulus measurements are set forth in
The following effects are observed from
A finite element analysis was performed to model various catheter formulations and geometries to compare responses to mechanical loading, including responses to radial crush and axial buckling. Sixteen different combinations of catheter geometries and materials were formed according to the provided information of
To analyze radial crush responses for each tested catheter, a rigid, stainless steel 1 mm diameter cylinder was displaced about 0.2 mm into a side wall of the catheter. The load was applied 6 mm from the tip of the tested catheter. To analyze axial buckling for each tested catheter, the entire bottom surface of the tested catheter was fixedly coupled to a fixed surface, and then an axial load was applied on the top surface of the tested catheter. The results of such testing can be found in
In this example, film coupons were prepared using EVA 3325A with a therapeutic agent loading of 55 wt. % meloxicam. Each coupon was prepared at a measured thickness of 90 μm with a meloxicam particle size of either d90=26 μm or d90=50 μm. For elution testing, each coated monofilament sample was immersed in phosphate buffered saline having a pH of 7.4 at sink conditions, incubated at 37° C. and shaking at 50 rpm for the duration of a 14-day study. At predetermined points throughout the elution study, aliquots were sampled from the solution with replacement, and meloxicam concentration was measured in the aliquots by absorbance.
In this example, EVA-meloxicam-coated nylon monofilaments were manufactured using a two-step hot melt extrusion process including a twin-screw extrusion compounding step wherein EVA 3325A and meloxicam were mixed to produce homogenous EVA-meloxicam pellets having a 55 wt. % meloxicam loading. The two-step hot process further included a single-screw extrusion shape-forming step. During the shape-forming step, the EVA-meloxicam pellets were fed into a single-screw extruder having a cross-head, which was used to apply a 100 μm thick coating of EVA-meloxicam onto a nylon monofilament having a 0.73 mm diameter, resulting in an EVA-meloxicam-coated nylon monofilament having a final overall diameter of 0.93 mm.
Coated monofilament samples were tested after both the twin screw extrusion step and the single screw extrusion step. All of the coated monofilament samples were unsterilized. For elution testing, each coated monofilament sample was immersed in phosphate buffered saline having a pH of 7.4 at sink conditions, incubated at 37° C. and shaking at 50 rpm for the duration of a 14-day study. At predetermined points throughout the elution study, aliquots were sampled from the solution with replacement. The concentration of meloxicam was measured in each aliquot by a meloxicam potency assay.
In this example, nylon monofilaments coated with polycaprolactone (“PCL”) and meloxicam coating were manufactured using a two-step hot melt extrusion process. The compounding step was completed using twin-screw extrusion to mix the PCL and meloxicam to produce homogenous PCL-meloxicam pellets. Specifically, the formulation was composed of Purasorb® PC17 (Corbion) with 50 wt. % meloxicam loading. The pellets were then fed into a single-screw extruder for the shape-forming process. The single-screw extruder had a cross-head to apply a PCL-meloxicam coating having a thickness of about 100 μm onto a nylon monofilament having a 0.73 mm diameter, resulting in PCL-meloxicam coated nylon monofilaments having an overall diameter of 0.93 mm. To evaluate the effect of the processing conditions on the meloxicam release from PCL-meloxicam coatings, the high and low values for the screw speed and processing temperature for the single-screw extrusion step were tested as outlined in Table 2 below. The final products were PCL-meloxicam coated nylon monofilaments, and a upon inspection of cross-sections, the coatings were found to be highly concentric as illustrated in
From a solvent extraction and meloxicam potency assay, the measured drug loading for all of the samples was approximately 49 wt. % meloxicam, which was consistent with the target nominal loading of 50 wt. % meloxicam. The results indicate that the processing conditions in this example, including screw speed and processing temperature, have minimal to no impact on the meloxicam loading level.
For elution testing, each coated monofilament sample was immersed in phosphate buffered saline having a pH of 7.4 at sink conditions, incubated at 37° C. and shaking at 50 rpm for the duration of a 14-day study. At predetermined points throughout the elution study, aliquots were sampled from the solution with replacement. The concentration of meloxicam was measured in each aliquot by a meloxicam potency assay.
Now referring to
Referring specifically to
Now referring to
Referring now to
As shown in
Referring additionally to
In this example, a two-shot cylinder mold having dimensions (e.g., wall thickness and length) representative of a commercial catheter was designed, wherein the first shot was a polymer-only liner material for providing mechanical integrity and the second shot was a PCL-meloxicam coating jacket for controlling release of meloxicam to local subcutaneous tissue. The cylinder mold included a plurality of inserts for differing wall thicknesses of the first and second shots and two lengths corresponding with 6 mm and 9 mm catheters. The mold also had dual gating to facilitate balancing of outflow and pressure. The core pin dimension was held constant at 0.432 mm. The minimum wall thickness was 0.076 for each of the first shot and the second shot, resulting in a minimum overall wall thickness of 0.152 mm and an overall minimum outer diameter of 0.736 mm. The maximum overall wall thickness was 0.254 mm with an overall maximum outer diameter of 0.940 mm.
The two-shot cylinder molded part was formed using a 20-ton Sodick (Model LP20EH2, Serial 1073) molding machine. The material used for the first shot was high density polyethylene (“HDPE”) Borealis Bormed HE7541-PH. The material used for the second shot was PC17, further discussed above in Example 12, having 50 wt. % meloxicam loading, supplied as pellets formed by twin-screw extrusion in a pre-processing compounding step. For the first shot, HDPE parts were produced at three different wall thicknesses: 0.076 mm, 0.102 mm, and 0.127 mm, for each of the 6 mm and 9 mm catheter lengths.
For the first shot of HDPE, the parts achieved complete fill for wall thicknesses down to 0.076 mm for both the 6 mm and 9 mm catheter lengths. All parts were easily removed from the core pin without use of a mold release.
Table 3 below shows the fill results for the second shot for the 6 mm and 9 mm catheter lengths, the meloxicam dose loaded in the coating, and the catheter dimensions achieved. The meloxicam dose loaded in each catheter part for the 6 mm length is within the range of 0.945-1.89 mg for the 14-day target dose and exceed this 14-day target dose range for the 9 mm length parts. The overall outer diameter for the two-shot molded catheters is 0.889-0.940 mm, which meets the guidance that the overall outer diameter of the catheter should not exceed 1 mm in this example.
Referring to
The release from the micro-molded parts (1700d) approached the minimum target release as compared to the over-extruded samples which approached the maximum target release (1700c). The release profile of the micro-molded parts (1700d) shows sustained release over 14 days with a relatively linear release curve. Upon further characterization of the two samples, a difference in surface texture was observed, which impacts the drug release. The over-extruded samples, as shown in
For EVA-meloxicam formulations and PCL-meloxicam formulations discussed above, coating thicknesses were calculated from the experimental results for different formulations. Referring to
The average release rate normalized to surface area was calculated from the in vitro elution results provided above. Specifically, the average release rate was calculated as the weighted average of the release rate over 14 days, since the release rate was not constant over the 14-day period. The average release rate was normalized to the surface area of the sample, depending on the catheter length. The following equations were used to calculate the coating thicknesses based on the experimental average release rates normalized to surface area, wherein m=mass, V=volume, p=density, w=weight fraction, A=area, r=radius, d=diameter, h=height, and ϕ=volume fraction. These calculations assume that the catheter is a hollow cylinder.
The equation for the overall radius of the catheter is as follows, wherein the target surface area and height are known:
Assuming there are no ends for the surface area of the catheter, the surface area may be simplified to:
A=2πrh
d
overall=2roverall
In order to determine if the coating thickness of the polymer-meloxicam layer has a sufficient amount of meloxicam to achieve the target meloxicam 14-day dose (0.945-1.89 mg), the mass of the meloxicam loaded in the coating was calculated based on the coating volume using the following equations. The equation for the coating volume is:
The equation for the mass of meloxicam loaded, based on the coating volume calculated above, is as follows, wherein the volume of the coating, density of the meloxicam, density of the polymer, and weight of the drug are known:
The equations for mass balance are as follows:
The equations for volume balance are as follows:
When substituting in the polymer mass, the equation becomes:
To solve for the meloxicam mass, the following equation was used:
If the mass of meloxicam was greater than or equal to the target 14-day meloxicam dose, then the coating thickness calculated based on the experimental average release rates, normalized to surface area, was reported. However, if the mass of meloxicam was below the target 14-day meloxicam dose, then the coating thickness was calculated based on the target meloxicam dose. In this case, the coating thickness based on the target meloxicam dose is greater than the coating thickness based on the experimental release rates. The coating thickness based on the target meloxicam dose was calculated according to the following equation:
d
overall=2roverall
Referring to
Referring to
Referring to
Referring to
Referring to
Tables 4 and 5 below provide the exemplary minimum wall thicknesses for each of the two tested polymer matrices at 6 mm, 9 mm, and 13 mm catheter lengths. Each of the provided measurements assumes a minimum target meloxicam dose of 0.945 mg, 100% release over a 14-day period, and a meloxicam loading of 55 wt. %. However, the measurements do not take into consideration the impact of surface area on release rate.
While embodiments of the invention have been described as having exemplary designs, the embodiments of the present disclosure may be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations of the disclosed embodiments using its general principles.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/037998 | 7/22/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63203461 | Jul 2021 | US |